107 related articles for article (PubMed ID: 3708574)
1. Variables affecting the killing of cultured human neuroblastoma cells with monoclonal antibody and complement.
Duerst RE; Ryan DH; Frantz CN
Cancer Res; 1986 Jul; 46(7):3420-5. PubMed ID: 3708574
[TBL] [Abstract][Full Text] [Related]
2. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
Duerst RE; Rose D; Frantz CN
Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
[TBL] [Abstract][Full Text] [Related]
3. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
5. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
6. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung NK; Saarinen UM; Neely JE; Landmeier B; Donovan D; Coccia PF
Cancer Res; 1985 Jun; 45(6):2642-9. PubMed ID: 2580625
[TBL] [Abstract][Full Text] [Related]
8. Monocyte cytotoxicity: evidence for multiple mechanisms of in vitro erythrocyte target killing. Trypan blue can both inhibit and enhance target lysis.
Hall RE; Muchmore AV; Blaese RM
J Reticuloendothel Soc; 1982 Sep; 32(3):233-46. PubMed ID: 7153988
[TBL] [Abstract][Full Text] [Related]
9. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
10. Anti-neuroblastoma monoclonal antibodies which do not bind to bone marrow cells.
Frantz CN; Duerst RE; Ryan DH; Gelsomino NL; Constine LS; Gregory PK
Prog Clin Biol Res; 1985; 175():485-99. PubMed ID: 3887430
[TBL] [Abstract][Full Text] [Related]
11. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
[TBL] [Abstract][Full Text] [Related]
12. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
Bindon CI; Hale G; Waldmann H
Eur J Immunol; 1988 Oct; 18(10):1507-14. PubMed ID: 2973413
[TBL] [Abstract][Full Text] [Related]
13. Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and Lyt-2, 3. II. Evidence that trypsin pretreatment of target cells removes a non-H-2 molecule important in killing.
Gromkowski SH; Heagy W; Martz E
J Immunol; 1985 Jan; 134(1):70-7. PubMed ID: 3880579
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
16. Heparin inhibition of antibody-dependent complement-mediated lysis.
Wesolowski J; Ault K; Houghton R; Parkman R
Exp Hematol; 1984 Oct; 12(9):700-5. PubMed ID: 6237929
[TBL] [Abstract][Full Text] [Related]
17. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
19. In vitro treatment of human acute lymphocytic leukemia cells in bone marrow with a cocktail of monoclonal antibodies.
Nakamura H; Hirayama F; Tatsumi Y; Tani Y; Kubota Y; Kanakura Y; Oguma S; Ueda T; Shibata H; Masaoka T
Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():537-42. PubMed ID: 6596454
[TBL] [Abstract][Full Text] [Related]
20. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.
Gordon J; Stevenson GT
Immunology; 1981 Jan; 42(1):13-7. PubMed ID: 6970171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
